The biotech arm of France’s Ipsen (Euronext: IPN) will present five new sub-analyses of the Phase III NAPOLI-1 trial at the American Society of Clinical Oncology’s Gastrointestinal Cancer Symposium (ASCO GI), which kicks off in San Francisco today.
The data is aimed at physicians, providing treatment strategies for pancreatic cancer being treated with Onivyde (irinotecan liposome injection) in combination with fluorouracil and leucovorin.
Lead investigator Andrea Wang-Gillam said: “Delays and dose reductions during the course of treatment frequently occurred in patients with metastatic pancreatic cancer who are generally fragile and weak from their illness.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze